While molecular targeted therapies, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors, have significantly helped patients with specific genetic alterations, only a minority of patients with NSCLC have these mutations [11]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.